

# The effect of Neuragen® on neuropathic pain: Double-blind, placebo-controlled clinical trial

<b>Submission date</b> 04/06/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 09/06/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 16/08/2011	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Li Li

**Contact details**  
Department of Kinesiology  
Louisiana State University  
Baton Rouge  
United States of America  
70803

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**

**Study objectives**  
Neuragen® reduces neuropathic pain more than placebo.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Institutional Review Board, Louisiana State University. Date of approval: 09/28/2007 (ref: 2754)

**Study design**

Double-blind, randomised, placebo-controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Peripheral neuropathy

**Interventions**

Topical application of Neuragen® vs placebo. Neuragen®/placebo is applied once each in random order and in a double-blind fashion. The applications are at least one week apart from each other. Pain is measured 30 minutes before and after the application, and tracked every hour for 8 hours.

Total duration of follow-up: 8 hours after each application

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Foot sole pain on 11-point numerical pain scale, measured 30 minutes before and after the Neuragen®/placebo application, and tracked every hour for 8 hours.

**Key secondary outcome(s))**

Duration of pain reduction. Pain is measured 30 minutes before and after the application, and tracked every hour for 8 hours.

**Completion date**

27/09/2008

**Eligibility****Key inclusion criteria**

1. Both males and females, over 21
2. Diagnosed neuropathic pain for more three months
3. Pain level between 3-8 on a 0-10 visual pain scale
4. Does not have mental and communication impairments

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairment

**Date of first enrolment**

01/10/2007

**Date of final enrolment**

27/09/2008

**Locations****Countries of recruitment**

United States of America

**Study participating centre**

Department of Kinesiology

Baton Rouge

United States of America

70803

**Sponsor information****Organisation**

Origin BioMed, Inc. (Canada)

**ROR**

<https://ror.org/008mcnd42>

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

Origin BioMed, Inc. (Canada)

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

#### **IPD sharing plan summary**

Not provided at time of registration